Recombinant erythropoietin differently affects proliferation of mesothelioma cells but not sensitivity to cisplatin and pemetrexed

Cancer Chemotherapy and Pharmacology

Volumn 61, Issue 5, 2008, Pages 893-901

  Palumbo, Camilla ^a   Battisti, Sonia ^a   Carbone, Daniela ^a   Albonici, Loredana ^a   Alimandi, Maurizio ^b   Bei, Roberto ^a   Modesti, Andrea ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Cisplatin; Epoetin beta; Erythropoietin receptor; Mesothelioma; Pemetrexed

Indexed keywords

CISPLATIN; ERYTHROPOIETIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PEMETREXED; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CELL GROWTH; CELL PROLIFERATION; CELL PROTECTION; CYTOTOXICITY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SENSITIVITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MALIGNANT MESOTHELIOMA; MITOGENESIS; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; DRUG INTERACTIONS; ERYTHROPOIETIN, RECOMBINANT; GENE EXPRESSION; GLUTAMATES; GUANINE; HUMANS; IMMUNOBLOTTING; MESOTHELIOMA; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ERYTHROPOIETIN;

EID: 39749119833     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0608-3     Document Type: Article

References (48)

1. Robinson BWS, Lake RA (2005) Advances in malignant mesothelioma. N Engl J Med 353:1591-1603
2. Tsiouris A, Walesby RK (2007) Malignant pleural mesothelioma: current concepts in treatment. Nat Clin Pract Oncol 4:344-352
3. Berghmans T, Paesmans M, Lalami Y, Louviaux I, Luce S, Mascaux C, Meert AP, Sculier JP (2002) Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 38:111-121
4. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Von Pawel J, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 22:1589-1597
5. Hazarika M, White RM Jr, Booth BP, Wang YC, Ham DYL, Liang CY, Rahman A, Gobburu JVS, Li N, Sridhara R, Morse DE, Lostritto R, Garvey P, Johnson JR, Pazdur R (2005) Pemetrexed in malignant mesothelioma. Clin Cancer Res 11:982-992
6. Bohlius J, Weingart O, Trelle S, Engert A (2006) Cancer-related anemia and recombinant human erythropoietin-an updated overview. Nat Clin Pract Oncol 3:152-164
7. Acs G, Acs P, Beckwith SM, Pitts RL, Clements E, Wong K, Verma A (2001) Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 61:3561-3565
8. Farrell F, Lee A (2004) The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist 9:18-30
9. Sytkowski AJ (2007) Does erythropoietin have a dark side? Epo signaling and cancer cells. Sci STKE 395:pe38
10. Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, Makhson A, Roth A, Dodwell D, Baselga J, Biakhov M, Valuckas K, Voznyi E, Liu X, Vervammen E (2005) Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 23:5960-5972
11. Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C, Frommhold H (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362:1255-1260
12. Osterborg A, Aapro M, Cornes P, Haselbeck A, Hayward CRW, Jelkmann W (2007) Preclinical studies of erythropoietin receptor expression in tumor cells: impact on clinical use of erythropoietic proteins to correct cancer-related anaemia. Eur J Cancer 43:510-519
13. Henke M, Mattern D, Pepe M, Bezay C, Weissenberger C, Werner M, Pajonk F (2006) Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 24:4708-4713
14. Sinclair AM, Todd MD, Forsythe K, Knox SJ, Elliott S, Begley CG (2007) Expression and function of erythropoietin receptors in tumors. Cancer 110:477-488
15. Reale FR, Griffin TW, Compton JM, Graham S, Townes PL, Bogden A (1987) Characterization of a human malignant mesothelioma cell line (H-MESO-1): a biphasic solid and ascitic tumor model. Cancer Res 47:3199-3205
16. Catalano A, Romano M, Robuffo I, Strizzi L, Procopio A (2001) Methionine aminopeptidase-2 regulates human mesothelioma cell survival: role of Bcl-2 expression and telomerase activity. Am J Pathol 159:721-731
17. Versnel MA, Bouts MJ, Hoogsteden HC, van der Kwast TH, Delahaye M, Hagemeijer A (1989) Establishment of human malignant mesothelioma cell lines. Int J Cancer 44:256-260
18. Kitamura T, Tojo A, Kuwaki T, Chiba S, Miyazono K, Urabe A, Takaku F (1989) Identification and analysis of human erythropoietin receptors on a factor-dependent cell line, TF-1. Blood 73:375-380
19. Keepers YP, Pizao PE, Peters GJ, van Ark-Otte J, Winograd B, Pinedo HM (1991) Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur J Cancer 27:897-900
20. Goldberg MA, Glass GA, Cunningham JM, Bunn HF (1987) The regulated expression of erythropoietin by two human hepatoma cell lines. Proc Natl Acad Sci USA 84:7972-7976
21. Westphal G, Niederberger E, Blum C, Wollman Y, Knoch TA, Rebel W, Debus J, Friedrich E (2002) Erythropoietin and G-CSF receptors in human tumor cells: expression and aspects regarding functionality. Tumori 88:150-159
22. Gewirtz DA, Di X, Walker TD, Sawyer ST (2006) Erythropoietin fails to interfere with the antiproliferative and cytotoxic effect of antitumor drugs. Clin Cancer Res 12:2232-2238
23. LaMontagne KR, Butler J, Marshall DJ, Tullai J, Gechtman Z, Hall C, Meshaw A, Farrell FX (2006) Recombinant epoteins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Mol Cancer Ther 5:347-355
24. Li F, Chong ZZ, Maiese K (2004) Erythropoietin on a tightrope: balancing neuronal and vascular protection between intrinsic and extrinsic pathways. Neurosignals 13:265-289
25. Richmond TD, Chohan M, Barber DL (2005) Turning cells red: signal transduction mediated by erythropoietin. Trends Cell Biol 15:146-155
26. Ramos-Nino ME, Vianale G, Sabo-Attwood T, Mutti L, Porta C, Heintz N, Mossmann BT (2005) Human mesothelioma cells exhibit tumor cell-specific differences in phosphatidylinositol 3-kinase/AKT activity that predict the efficacy of Onconase. Mol Cancer Ther 4:835-842
27. Westenfelder C, Baranowski RL (2000) Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidey Int 58:647-657
28. Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M (1990) Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA 87:5987-5982
29. Storring PL, Tiplady RJ, Gaines Das RE, Stenning BE, Lamikanra A, Rafferty B, Lee J (1998) Epoetin alfa and beta differ in their erythropoietin isoform composition and biological properties. Br J Haematol 100:78-89
30. Yuen CT, Storring PL, Tiplady RJ, Izquierdo M, Wait R, Gee CK, Gerson P, Lloyd P, Cremata JA (2003) Relationship between the N-glycan structures and biological activities of recombinant human erythropoietins produced using different culture conditions and purification procedures. Br J Haematol 121:511-526
31. Kim JH, Lee KW, Jung Y, Kim TY, Ham HS, Jong HS, Jung KH, Im SA, Kim TY, Kim NK, Bang YJ (2005) Cytotoxic effects of pemetrexed in gastric cancer cells. Cancer Sci 96:365-371
32. Gordon GJ, Mani Madhubalan, Maulik G, Mukhopadhyay L, Yeap BY, Kindler HL, Salgia R, Sugarbaker DJ, Bueno R (2007) Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemother Pharmacol, Epub ahead of print
33. Min SH, Goldman ID, Zhao R (2007) Caffeine makedly sensitized human mesothelioma cell lines to pemetrexed. Cancer Chemother Pharmacol, Epub ahead of print
34. Kayser K, Gabius HJ (1992) Analysis of expression of erythropoietin- binding sites in human lung carcinoma by the biotinylated ligand. Zentralbl Pathol 138:266-270
35. Elliott S, Busse L, Bass MB, Lu H, Sarosi I, Sinclair AM, Spahr C, Um M, Van G, Begley CG (2006) Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 107:1892-1895
36. Butnor KJ, Nicholson AG, Allred DC, Zander DS, Henderson DW, Barrios R, Haque AK, Allen TC, Killen DE, Cagle PT (2006) Expression of renal cell carcinoma-associated markers erythropietin, CD10, and renal cell carcinoma marker in diffuse malignant mesothelioma and metastatic renal cell carcinoma. Arch Pathol Lab Med 130:823-827
37. Hardee ME, Arcasoy MO, Blackwell KL, Kirkpatrick JP, Dewhirst MW (2006) Erythropoietin biology in cancer. Clin Cancer Res 12:332-339
38. Stolze I, berchner-Pfannschmidt U, Freitag P, Wotzlaw C, Rossler J, Frede S, Acker H, Fandrey J (2002) Hypoxia-inducible erythropoietin gene expression in human neuroblastoma cells. Blood 100:2623-2628
39. Kumar SK, Acs G, Fang D, Herlyn M, Elder DE, Xu X (2005) Functional erythropoietin autocrine loop in melanoma. Am J Pathol 166:823-830
40. Hardee ME, Cao Y, Fu P, Jiang X, Zhao Y, Rabbani ZN, Vujaskovic Z, Dewhirst MW, Arcasoy MO (2007) Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression. PloS ONE 2:e549
41. Dunlop EA, Percy MJ, Boland MP, Maxwell AP, Lappin TR (2006) Induction of signalling in non-eyrthroid cells by pharmacological levels of erythropoietin. Neurodegener Dis 3:94-100
42. Erickson-Miller CL, Pelus LM, Lord KA (2000) Signaling induced by erythropoietin and stem cell factor in UT-7/Epo cells: transient versus sustained proliferation. Stem Cells 18:366-373
43. Feldman L, Wang Y, Rhim JS, Bhattacharya N, Loda M, Sytkowski AJ (2006) Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells. Prostate 66:135-145
44. Lai SY, Childs EE, Xi S, Coppelli FM, Gooding WE, Wells A, Ferris RL, Grandis J (2005) Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene 24:4442-4449
45. Acs G, Zhang PJ, McGrath CM, Acs P, McBroom J, Mohyeldin A, Liu S, Lu H, Verma A (2003) Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Am J Pathol 162:1789-1806
46. Belenkov AI, Shenouda G, Rizhevskaya E, Cournoyer D, Belzile JP, Souhami L, Devic S, Chow YK (2004) Erythropoietin induces cancer cell resistance to ionizing radiation and to cisplatin. Mol Cancer Ther 3:1525-1532
47. McBroom JW, Acs G, Rose GS, Krivak TC, Mohyeldin A, Verma A (2005) Erythropoietin receptor function and expression in epithelial ovarian carcinoma. Gynecol Oncol 99:571-577
48. Liu WM, Powles T, Shamash J, Propper D, Oliver T, Joel S (2004) Effect of haemopoietic growth factors on cancer cell lines and their role in chemosensitivity. Oncogene 23:981-990